Dear all, this new classroom is just in the planning stage, let's make it happen! The idea is to create a crowdsourced classroom where members share real-life progress stories, connect with other members, and find renewed hope. What’s a story of progress and success? Any win, big or small. Remission, or just moving forward. Let's start small; we've got some recent success stories. @Jeff Boldrick , @Whitney Khan , can we post yours in the classroom to kick things off? Also recalling @Odette Rocha , @Michelle Love and @Hengameh Bolouri had great stories, if I remember correctly. Can we add yours too? Others with great stories, please share! No, it's not bragging, it's giving hope to others. Moving forward, all admins can add member success stories from the community to the classroom (with permission). How does that sound?

Hi all, this is a great lecture by the highly intelligent and humble Dr Tomas Duraj - a research partner of Prof. Seyfried who kindly wrote the foreword for my book. Obviously Prof. Seyfried is the GOAT, but I find Dr Duraj’s presentations about metabolic therapy and in particular his explanation of OXPHOS and AMPK much easier to digest.

Merry christmas everyone! I'm just listening to the latest podcast with Dr Casey Peavler and Tomas Duraj and they mention adding in carnitine to aid with ketosis. Has anyone tried this or have any experience with carnitine? https://youtu.be/DnKKsXBIxOY?si=Ugdze4WngJFxMyPo

https://www.facebook.com/share/p/1CU1QfHe5u/ Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research: Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties. Background: Why Mebendazole Matters Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated: Microtubule inhibition in cancer cells Disruption of glucose metabolism in malignant tissues Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2) Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable. What Johns Hopkins Has Patented The new patent centers on: Polymorph C — a redesigned crystalline form This form appears to demonstrate: Improved oral absorption Higher plasma concentrations Prolonged systemic exposure Greater potency in killing cancer cells in vitro compared with existing polymorphs This is scientifically notable, because mebendazole traditionally suffers from: Poor gastrointestinal absorption High inter-individual variability Low bioavailability unless taken with high-fat meals A more bioavailable crystalline form directly addresses these limitations. Synergy Through Transporter Inhibition The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of: P-glycoprotein (P-gp) Breast Cancer Resistance Protein (BCRP) These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.

Hey guys, I was hoping to hear how people's experience with radiation has been. My dad has stage 3 lung cancer, diagnosed in July 2025. He has had one round of chemotherapy (carboplatin) and immunotherapy (pembrolizumab) but unfortunately had a severe reaction with deranged liver function. He's been on prednisolone and mycophenolate since September to manage the liver issues, which have now thankfully normalised, he's on a weaning steroid dose now. He has been on a ketogenic diet with ivermectin since August and was on fenbendazole when his liver went off. We have stopped the fenben in case it was contributing. No more chemo for now because of the immunosuppression. He had a repeat CT scan this week which shows stable known lymph node and primary, with 2 new non-descript ground glass nodules inthe lung near his kn own primary. Unclear significance at this stage. They are now suggesting a few weeks of radiation to the lymph nodes in his chest. We are cautious of the radiation given the extreme side effect of the other conventional treatments which have affected our ability to really give metabolic therapy a proper go. Does anyone have any thoughts or experience they could share? Thanks